$-0.02 EPS Expected for Enzo Biochem, Inc. (ENZ)

September 17, 2017 - By Linda Rogers

 $ 0.02 EPS Expected for Enzo Biochem, Inc. (ENZ)
Investors sentiment increased to 1.29 in Q4 2016. Its up 0.05, from 1.24 in 2016Q3. It increased, as 9 investors sold Enzo Biochem, Inc. shares while 29 reduced holdings. 13 funds opened positions while 36 raised stakes. 23.43 million shares or 0.05% more from 23.42 million shares in 2016Q3 were reported.
Mckinley Ltd Delaware stated it has 0.09% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). 81,446 were accumulated by Corsair Mgmt L P. Bancorp Of New York Mellon reported 0% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Susquehanna Ltd Liability Partnership holds 59,969 shares. Millennium Management Lc, New York-based fund reported 101,622 shares. Pennsylvania-based Sei Investments has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ). Deutsche Fincl Bank Ag invested in 0% or 27,818 shares. Bridgeway Mngmt, Texas-based fund reported 322,700 shares. City reported 120 shares. Walleye Trading Ltd Limited Liability Company holds 0% or 38,100 shares in its portfolio. Blackrock Fund Advsr accumulated 1.28 million shares. Citigroup invested in 0% or 40,895 shares. Nine Chapters Capital Limited Liability Company owns 30,900 shares. Vanguard Gru holds 0% or 1.53 million shares in its portfolio. Tfs Ltd Liability Corporation invested in 0.03% or 17,209 shares.

Since June 13, 2017, it had 0 buys, and 1 sale for $160,054 activity.

Wall Street await Enzo Biochem, Inc. (NYSE:ENZ) to release earnings on October, 12. Analysts forecast earnings per share of $-0.02, up exactly $0.02 or 50.00 % from 2014’s $-0.04 EPS. The stock decreased 0.73% or $0.08 on September 15, reaching $10.86. About 391,420 shares traded or 142.73% up from the average. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since September 17, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce services and products. The company has market cap of $502.73 million. The Company’s divisions include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. It has a 15.26 P/E ratio. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Seekingalpha.com which released: “Enzo Biochem’s (ENZ) Management on Q4 2016 Results – Earnings Call Transcript” on October 14, 2016, also Seekingalpha.com with their article: “Enzo Biochem (ENZ) on Q3 2017 Results – Earnings Call Transcript” published on June 09, 2017, Businesswire.com published: “Enzo Biochem Reports Delaware Court Ruling” on June 29, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Seekingalpha.com and their article: “Enzo Biochem Rounds The Corner” published on July 10, 2017 as well as Zacks.com‘s news article titled: “Looking for a Top Momentum Stock? 3 Reasons Why Enzo Biochem (ENZ) is a Great …” with publication date: June 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: